¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2019 ´ëÇѳ»ºÐºñÇÐȸ Çп¬»ê ¹× Ãß°èÇмú´ëȸ : 2019-11-01

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2019 ´ëÇѳ»ºÐºñÇÐȸ Çп¬»ê ¹× Ãß°èÇмú´ëȸ : 2019-11-01
±³À°ÀÏÀÚ : 2019-11-01
±³À°Àå¼Ò : ´ëÀüÄÁº¥¼Ç¼¾ÅÍ  
±³À°ÁÖÁ¦ : 2019 ´ëÇѳ»ºÐºñÇÐȸ Çп¬»ê ¹× Ãß°èÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇѳ»ºÐºñÇÐȸ
´ã´çÀÚ : ´ëÇѳ»ºÐºñÇÐȸ Ãß°èÇмú´ëȸ »ç¹«±¹
¿¬¶ôó : 070-7433-1755  
À̸ÞÀÏ : kes@cdmthebig.com      
±³À°Á¾·ù : ³»°úÀÇ»çÇÐ
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ´ëÀü±¤¿ª½Ã
±³À°½Ã°£ : 20 ½Ã°£ 48ºÐ  
¼¼ºÎ¼ö°­·á : 130,000¿ø      
ºñ°í ¸¸ 65¼¼ ÀÌ»ó Æò»ý ȸ¿ø, Àü°øÀÇ, Çлý(Çкλý, ´ëÇпø»ý) [»çÀü,ÇöÀå ¹«·á]±ºÀÇ°ü, °øÁߺ¸°ÇÀÇ, °£È£»ç, ¿µ¾ç»ç [»çÀü 5¸¸¿ø / ÇöÀå 6¸¸¿ø]Àü¹®ÀÇ / ÀüÀÓÀÇ / ±âÃÊÀÇÇÐÀÚ (ȸ¿ø - Æò»ýȸ¿ø/Á¤È¸¿ø) [»çÀü 10¸¸¿ø / ÇöÀå11¸¸¿ø]Àü¹®ÀÇ / ÀüÀÓÀÇ / ±âÃÊÀÇÇÐÀÚ (ºñȸ¿ø) [»çÀü 12¸¸¿ø / ÇöÀå13¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-01 Room1 09:00~09:30 Management of thyroid nodules with Bethesda III, IV cytology  ±èÅÂÇõ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11-01 Room1 09:30~10:00 Strategy for follow up of DTC with low to intermediate risk of recurrence  ±èº¸Çö(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 11-01 Room1 10:00~10:30 Thyroid dysfunction after cancer immunotherapy  À±ÁöÈñ(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 11-01 Room2 09:00~09:30 From clinical observations to target identification and therapeutic development  Philip C. Tagari(Amgen) 
±³À°½Ã°£ 11-01 Room2 09:30~10:00 Hit to Lead Process for Innovative Drug Discovery  ÀÌ°æ(µ¿±¹´ë ¾àÇаú) 
±³À°½Ã°£ 11-01 Room2 10:00~10:30 Accelerating drug discovery using a data-driven AI plaform  ÀÌÁö¿µ(´ë±¸°æºÏ÷´ÜÀÇ·á»ê¾÷ÁøÈïÀç´Ü) 
±³À°½Ã°£ 11-01 Room3 09:00~09:30 Role of Senescent T cells in Prediabetes  ÀÌÇö½Â(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 11-01 Room3 09:30~10:00 Role of Metformin in inhibiting estrongen induced proliferation and regulating estrogen receptor expression in papillary thyroid carcinoma  ÀÌÀμ®(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 11-01 Room3 10:00~10:30 Effect of statin and ezetimibe on insulin resistance with prediabetes  È«ÁØÈ­(À»ÁöÀÇ´ë) 
±³À°½Ã°£ 11-01 Room4 09:00~09:30 °æµ¿¸ÆÃÊÀ½ÆÄÀDZâÃÊ(physics, Doppler, spectrum analysis)  À±¼®±â(õ¾È¿£µµ³»°ú) 
±³À°½Ã°£ 11-01 Room4 09:30~10:00 °æµ¿¸Æ ÇöóÅ©/ÇùÂøÀÇ Æò°¡  ±è¼ö°æ(Â÷ÀÇ°úÇдë) 
È޽Ġ11-01  10:30~10:50 Coffee Break  () 
±³À°½Ã°£ 11-01 Room1 10:50~11:20 Comparison of direct renin assay and plasma renin activity assay  À̾ƶ÷(³ì½ÊÀÚÀÇ·áÀç´Ü Áø´Ü°Ë»çÀÇÇкΠƯ¼ö»ýÈ­ÇÐÀ¯´Ö) 
±³À°½Ã°£ 11-01 Room1 11:20~11:50 perioperative hemodynamic instability in pheochromocytoma  ±è¼öÁø(¼­¿ïÀÇ´ë ¿Ü°ú) 
±³À°½Ã°£ 11-01 Room1 11:50~12:20 ºÎ½ÅÈ£¸£¸ó µî·Ï»ç¾÷: Çѱ¹ÀΠŸ¾× ³» ÄÚ¸£Æ¼¼Ö Âü°íÄ¡ Á¤¸³  ±èÈ¿Á¤(À»ÁöÀÇ´ë) 
±³À°½Ã°£ 11-01 Room2 10:50~11:20 Prime opportunity - License to heal  Á¤ÀçÈ£(¿¬¼¼ÀÇ´ë ¿Ü°ú) 
±³À°½Ã°£ 11-01 Room2 11:20~11:50 When, how and what do I do for the strong patent?  ·ùÁ¾¿ì(Á¦ÀÏƯÇã¹ýÀÎ) 
±³À°½Ã°£ 11-01 Room2 11:50~12:20 How to secure budgets for investigator initiated trials?  Á¶¿µ¹Î(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-01 Room3 10:50~11:10 Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer  ±è¹ÎÁÖ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-01 Room3 11:10~11:30 Expression of NF2 Modulates the Progression of BRAFV600E Mutated Thyroid Cancer Cells  À¯¹ÌÇö(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 11-01 Room3 11:30~11:50 Functional Identification of Compound Heterozygous Mutations in the CYP17A1 Gene Resulting in Combined 17¥á-Hydroxylase/17,20-Lyase Deficiency  ¸ðÀº¿µ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 11-01 Room3 11:50~12:10 Triglyceride Glucose Index Is Superior to the Homeostasis Model Assessment of Insulin Resistance for Predicting Nonalcoholic Fatty Liver Disease in Korean Adults  ÀÌ»ó¹è(¿¬¼¼ÀÇ´ë ³ë³â³»°ú) 
±³À°½Ã°£ 11-01 Room3 12:10~12:20 Q & A ¹× ÅäÀÇ  () 
±³À°½Ã°£ 11-01 Room4 10:50~11:12 Highly efficient base-editing in mice  ±è°æ¹Ì(°í·ÁÀÇ´ë »ý¸®Çб³½Ç) 
±³À°½Ã°£ 11-01 Room4 11:12~11:34 Parallel neural pathways for habit and controlled behavior in the primate brain  ±è Çü(¼­¿ï´ë »ý¸í°úÇкÎ) 
±³À°½Ã°£ 11-01 Room4 11:34~11:56 New Candidate Genes for Metabolic Syndrome from Systemic Mouse Metabolic Phenotyping  ¼ºÁ¦°æ(¼­¿ï´ë ¼öÀÇÇаú/KMPC) 
±³À°½Ã°£ 11-01 Room4 11:56~12:18 Analysis of skeletal tissue diseases using genetically modified mouse models  ÃÖÁ¦¿ë(°æºÏÀÇ´ë »ýÈ­ÇС¤¼¼Æ÷»ý¹°Çб³½Ç) 
½Ä»ç 11-01 Room1 12:20~13:10 Luncheon Lecture I  () 
½Ä»ç 11-01 Room2 12:20~13:10 Luncheon Lecture II  () 
±³À°½Ã°£ 11-01 Room1 13:10~13:50 Digital healthcare: Can it open the new era of patients management?  À±°ÇÈ£(°¡Å縯ÀÇ´ë) 
È޽Ġ11-01  14:15~14:30 Coffee Break  () 
±³À°½Ã°£ 11-01 Room5 14:00~14:30 Hands-on  À±¼®±â(õ¾È¿£µµ³»°ú) 
±³À°½Ã°£ 11-01 Room5 14:30~15:00 Hands-on  ±èÁ¾È­(ºÎõ¼¼Á¾º´¿ø) 
±³À°½Ã°£ 11-01 Room1 14:30~15:00 Remodeling of calcified endplate by teriparatide (rhPTH 1-34), a potential treatment of osteoporosis with discogenic low back pain  Zou Xuenong(Sun Yat-sen University) 
±³À°½Ã°£ 11-01 Room1 15:00~15:30 Senescent phenotypes of chondrocytes govern the pathogenesis of osteoarthritis.  ±èÁøÈ«(¼­¿ï´ë »ý¸í°úÇкÎ) 
±³À°½Ã°£ 11-01 Room1 15:30~16:00 Overcoming osteoporosis and beyond: Locomotive syndrome or dysmobility syndrome (tentative)  À̽ÃÈÆ(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 11-01 Room2 14:30~15:00 ½Å¾àÈĺ¸ ¹°ÁúÀ» ¾î¶² °üÁ¡À¸·Î Æò°¡Çؼ­ ȸ»ç¿¡¼­ ±â¼úÀÌÀüÀ» ¹Þ´Â °áÁ¤À» ÇÏ´ÂÁö? (±â¼úÀ» »ç´Â ÀÔÀå)(¹ÌÁ¤)  ÀÌÁ¤±Ô(ºê¸´Áö¹ÙÀÌ¿À) 
±³À°½Ã°£ 11-01 Room2 15:00~15:30 Strategies and Solutions to Partnering with Pharma  Chris Vlahos(lpsen) 
±³À°½Ã°£ 11-01 Room1 16:00~16:30 Metabolic characteristics of patients with acromegaly  Zhaoyun Zhang(Huashan Hospital Fudan University) 
±³À°½Ã°£ 11-01 Room1 16:30~17:00 Progress in the genetic study of pituitary adenomas  Qilin Zhang(Neurosurgery, Huashan Hospital Fudan University) 
±³À°½Ã°£ 11-01 Room1 17:00~17:30 Hypophysectomized Rats and Pituitary Transplantation  ¾ç½ÂÈ£(°¡Å縯ÀÇ´ë ½Å°æ¿Ü°ú) 
±³À°½Ã°£ 11-01 Room2 15:30~16:00 ÀÇ·á µ¥ÀÌÅ͸¦ ÀÌ¿ëÇÑ µö·¯´× ±â¼ú °³¹ßÀÇ °úÁ¤  ±è±âȯ(·ç´Ö) 
±³À°½Ã°£ 11-01 Room2 16:00~16:30 ÀÓ»óÀÇ°¡ ½ÃÀÛÇÏ´Â Medical informatics ¿¬±¸  À±´ö¿ë(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 11-01 Room2 16:30~17:00 ºí·ÏüÀΰú ÇコÄɾî, ±×¸®°í °³Àΰǰ­±â·Ï(PHR)  ÀÌÀº¼Ö(¸Þµðºí·Ï) 
±³À°½Ã°£ 11-01 Room2 17:00~17:30 A lagre population based genome study for Type 2 diabetes  ±èºÀÁ¶(Áúº´°ü¸®º»ºÎ À¯Àüü¿¬±¸°ú) 
±³À°½Ã°£ 11-01 Room3 16:00~16:25 °Ç°­º¸ÇèÁ¤Ã¥ÀÇ º¯È­ ¹æÇâ  ÀÌÁß±Ô(º¸°Çº¹ÁöºÎ) 
±³À°½Ã°£ 11-01 Room3 16:25~16:50 ¿ø°¡ºÐ¼® Çʿ伺 ¹× È°¿ë¹æ¾È" (±Þ¿©Àü·«½Ç ¿ø°¡ºÐ¼®ºÎÀå)  ±èÁö¿µ(±¹¹Î°Ç°­º¸Çè°ø´Ü) 
±³À°½Ã°£ 11-01 Room3 16:50~17:15 3Â÷ »ó´ë°¡Ä¡ °³Æí ÇöȲ ¹× °úÁ¦  ¹®°æ¾Æ(°Ç°­º¸Çè½É»çÆò°¡¿ø) 
±³À°½Ã°£ 11-01 Room3 17:15~17:40 Panel Discussion  ¹Ú°æÇý(±¹¹Î°Ç°­º¸Çè Àϻ꺴¿ø) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2019 ´ëÇѳ»ºÐºñÇÐȸ Çп¬»ê ¹× Ãß°èÇмú´ëȸ : 2019-11-01""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѺñ´¢ÀÇÇÐȸ 2019 Annual Meeting of KUA : 2019-11-01
´ÙÀ½±Û ¼¼ºê¶õ½ºº´¿ø Next Generation Precision medicine: Bridging biology and drug development in precision oncology : 2019-11-01
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 81 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 44 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 53 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 57 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 50 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 47 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 23 2024-05-11
20687 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22 0 18 2024-05-11
20686 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21 0 46 2024-05-11
20685 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21 0 23 2024-05-11
20684 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 1 : 2024-06-20 0 18 2024-05-11
20683 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ (¿Â¶óÀÎ) ¼­¿ï°æÀÎÁöȸ 277Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-18 0 53 2024-05-11
20682 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦3Â÷ ¿¬¼ö±³À°(¿°Áõ¼º ÀåÁúȯ,ºñ¸¸ ¾à¹° Ä¡·á ) : 2024-06-17 0 31 2024-05-11
20681 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ¿¬¼ö°­Á : 2024-06-16 0 39 2024-05-11
20680 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 2Â÷ : 2024-06-15 0 33 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷